Sickle Cell Disease Association of America, Inc. (SCDAA)
About SCDAA
Sickle Cell Research & Screening
Member Organizations
Media Canter
Annual Convention
Sickle Cell Programs & Eduation
Get Involved
Calendar of Events
Wall of Giving
Join SCDAA
SCDAA
Address
Sickle Cell Disease Association of America, Inc.
3700 Koppers Street
Suite 570
Baltimore, Maryland 21227

Office   410.528.1555
Fax   410.528.1495
Toll Free   800.421.8453


Monday - Friday:
9:00am - 5:00pm (EST)

scdaa@sicklecelldisease.org
  • Sickle Cell Conditions
News & Press
Media Center / News & Press

Pfizer Announces Enrollment Of First Patient In Phase 3 Trial

Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older.

NHLBI Forum “Engaging the Community: Developing Solutions”

The National Heart, Lung, and Blood Institute will host a Sickle Cell Disease Forum, “Engaging the Community: Developing Solutions” on June 25-26, 2015 in Bethesda, Maryland.

The SCDAA has been awarded the Health Resources and Services Administration (HRSA), Sickle Cell Disease Newborn Screening Program Grant!

SCDAA has been designated to serve as the National Backbone Organization for the HRSA Sickle Cell Disease Newborn Screening Program. As the national backbone organization SCDAA will work with community-based organizations across the country to implement a strengthened approach to care, collective impact and strategic activities within the Sickle Cell community.

Grace Ojei SCD Overcomer Scholarship

The Grace Ojei SCD Overcomer Scholarship is developed for high school seniors entering into college or college students that have particularly worked to overcome obstacles and eliminate barriers to achieve their goals. Due Friday June 29, 2015

Sickle Cell Disease Research, Surveillance, Prevention & Treatment Act of 2015

SCDAA along with its members, advocates and champions received tremendous news during the Annual Sickle Cell Disease Advocacy Day. On the morning of Thursday - April 16, 2015 Representatives Danny K. Davis (D-IL) and Michael C. Burgess (R-TX) revealed the reintroduction of bipartisan legislation H.R. 1807

Breaking News: FDA Approves New Formulation of Iron Chelator

The US Food and Drug Administration (FDA) has approved a new oral formulation of deferasirox. The tablet will be marketed as Jadenu by Novartis, who also market Exjade, which has been the standard deferasirox formulation for the past 10 years.

Sickle Cell Disease Association of America, Inc.